China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with 128,000 employees and a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services.
Sinopharm owns over 1,100 subsidiaries and 6 listed companies which are Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., and China Traditional Chinese Medicine Holdings Co., Ltd.
The past years witnessed Sinopharm’s steady and sound development. From 2009to 2018, the CAGR of revenue and total assets reached 24.24% and 30.54%, respectively. Sinopharm ranked 169th in Fortune Global 500, and the revenue of 2018 amounted to nearly 400 billion RMB.
Sinopharm has built a nationwide logistic and distributing network for drugs and medical devices and equipment, including 5logistic hubs, more than 40 provincial-level centers, and over 240 municipal-level logistic sites. By establishing the smart medical service system, Sinopharmdelivers quality services of more than 230,000 corporate clients.
Sinopharm has an applied pharmaceutical research institute and an engineering design institute, both taking a leading position in China. Two Academicians of the Chinese Academy of Engineering, 11 national R&D institutes, 44 provincial-level technology centers, and over 5,000 scientists have made remarkable achievements. Sinopharm also chaired in setting over 530 national technical criteria, among which the EV71 vaccine, the first category new drug of China with Sinopharm holding complete independent intellectual property rights, reduces the morbidity of hand-foot-and-mouth disease among Chinese children. The R&D and launch of sIPV ensure the progress of the national immunization program for polio.
Sinopharm has built up manufacturing and medicinal materials sites for biological drugs, narcotic and psychotropic drugs, anti-infectious drugs, oncology drugs, cardio-vascular drugs and respiratory drugs. Some of the production lines have been approved by the US FDA and EU authorities, and prequalified by WHO.
As world’s 6th largest vaccine manufacturer, Sinopharm is able to produce all the vaccines in the National Vaccination Program and is the supplier of over 80% vaccines used in the Expanded Program on Immunization in China.
Sinopharm leads in TCM sector by establishing an integrated TCM industry chain that covers planting, R&D, pieces for decoction, formulated instant granules, and preparations. It is able to produce over 900 medicines,owns 15 China Time-honored Brands and 4 National Intangible Cultural Heritage medicines.
Sinopharmhas fostered 30 highly recognized events represented by CMEF (China International Medical Equipment Fair), serving the entire chain and many subdivisions concerning healthcare. These exhibitions and conferences have become a platform for exchange and cooperation that advances the whole industry.
Sinopharm explored a new model of drugstores with extensive healthcare services. There are over 5,100 chain drugstores under the brands of Guoda, Jinxiang, Dadesheng, and Tianyitang, providing convenient access for customers. Sinopharm forms a healthcare network consisting of regional healthcare groups in provinces of Henan, Hubei, Liaoning, and Heilongjiang. Sinopharm provides easier access to healthcare services for the people in dozens of our medical institutions, with more than 10,000 beds in total.
Sinopharm broadens its international cooperation by founding 26 joint ventures with world-renowned pharmaceutical companies and trading with more than 120 countries and regions, including60 Belt and Road countries.
The JE vaccine, of which Sinopharm owns complete independent intellectual property rights, has been listed in the procurement catalog by the UN organizations to benefit the whole world. Sinopharm’s production sites in Vietnam and Malaysia, along with the China-aided hospitals and mobile clinics constructed by Sinopharm in Myanmar and Cambodia, provide not only jobs for the local people but also make significant contributions to their well-beings.
As healthcare-centered financial services develop, an industry-and-finance model with Sinopharm features takes shape.
Sinopharm acts as the president enterprise in many influential associations such as China Pharmaceutical Industry Association, China National Narcotic Drugs Association, China Association of Pharmaceutical Commerce, etc., and plays its role in preventing diseases, safeguarding people’s health, and advancing the whole industry.

In 2001, Hainan Sihuan Pharmaceutical Co., Ltd. was founded, marking the starting point of the entrepreneurial development of Sihuan Pharmaceutical Holdings Group. At its start stage, Sihuan Pharmaceutical attached great importance to marketing. Later, with the establishment of Hainan Sihuan Cardio-Cerebral Vascular Drug Research Institute, it is able to make progress both in market development and new product R&D, thus facilitating the company to develop rapidly. Later, through capital operation such as merger and acquisition, it further improved its industrial chain by successively incorporating Beijing Sihuan Pharmaceutical, Shenzhen Sihuan Pharmaceutical, and other companies into Sihuan Pharmaceutical, developing into a pharmaceutical group with integrated R&D, production and sales capabilities.
Sihuan Pharmaceutical Holdings Group was incorporated in Bermuda in April 2006 and was successfully listed in Singapore in March 2007. In 2009, in order to meet the needs of greater development, Sihuan Pharmaceutical Holdings Group completed privatization and was delisted from Singapore, and was successfully re-listed in Hong Kong in 2010.
Up to now, Sihuan Pharmaceutical Holdings Group has developed into a pharmaceutical enterprise with strong R&D capabilities, high-quality product structure, and a sound production management system. Together with a unique marketing model and professional services, it deeply engages in the cardio-cerebral vascular drug industry in China to serve human health, winning wide acclaim from the community and users, and has established a unique brand image of “Sihuan”.

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China. Fosun Pharma has built a strong root in China and developed a global operation strategy, with pharmaceutical manufacturing and R&D being the largest and core business segment, together with a strong presence in medical devices and diagnostics, healthcare services, pharmaceutical distribution, and retail.
With R&D innovation as a core driving factor, Fosun Pharma continues to optimize its pharmaceutical operations across both innovative and generic drugs. The company has established international R&D centers for excellence in areas such as innovative small molecule drugs, high-value generic drugs, biologics, and cell therapy.
Under the guidance of our 4IN strategy (Innovation, Internationalization, Integration, and Intelligentization), Fosun Pharma follows the brand concept of Innovation for Good Health and strives to be a leading enterprise in the global pharmaceutical and healthcare markets.

Haohai Biological Technology (06826.HK) is a leading company in China, focusing on R&D, manufacturing, and sales of biomedical materials. We strategically target the fast-growing therapeutic areas in the biomedical materials market, including ophthalmology, medical aesthetics and wound healing, orthopedics, and anti-adhesion and hemostasis. We currently manufacture intraocular lenses (IOL), medical sodium hyaluronate, medical chitosan, medical collage sponge, rhEGF, etc. Based on the sales volume of the Company’s IOL and the number of national cataract surgery cases, the company has captured about 30% of the IOL market in the PRC. Meanwhile, the market share of the company’s anti-adhesion products, OVD products, and orthopedics viscosupplementation products was 49.05%, 45.93%, and 36.21%, respectively. 
We believe our R&D capabilities will be the driving force behind our long-term competitiveness, as well as our future growth and development. The company’s in-house R&D team comprised of more than 200 staff members. In 2017, The Company was included in the list of National Enterprise Technology Centers. Also, the company owns one national postdoctoral R&D workstation and one Shanghai municipal academician expert workstation. Haohai Biological Technology had been granted more than 40 invention patents. Moreover, our proprietary medical chitosan and rhEGF was awarded the Second Prize of National Science and Technology Progress” by the State Council.